OUR MISSION
The global psychedelics industry is expected to be worth over US$100 billion with the potential to save $1 trillion on lost productivity, disrupting the way we approach healthcare. As attitudes towards psychedelics shift dramatically, we are witnessing an international rise in clinical trials, academic research and commercial investment. The use of psychedelics as medicine is set to open up a new industry at pace. We help investors, operators and regulators navigate the many opportunities through data, intelligence and networking.
PSYCH VIRTUAL INVESTOR SUMMIT
EUROPE AND ASIA
Join us on 21st April for the launch of our first PSYCH Investor Summit: Europe & Asia for a day of networking, pitches and keynotes.
The PSYCH Investor Summit: Europe & Asia is an opportunity to engage with distinguished industry leaders, rising entrepreneurs and global psychedelics investors to share insights and help develop this emerging frontier.
OFFERING
We demystify the legislative and regulatory environment surrounding a variety of psychedelics, helping our clients to navigate the changing landscape of each region.
We provide market forecasts and estimates for potential savings to society/economy which are likely to result from psychedelic therapies over the next decade.
We identify and analyse emerging trends for individual psychedelic therapies and monitor innovation and developments in this exciting, burgeoning industry.
DISRUPTING MODERN HEALTHCARE
Medical psychedelics are experiencing a renaissance, pushing forward the frontiers of healthcare innovation. The Psychedelics as Medicine Report: Second Edition provides unparalleled consumer insights and market intelligence from experts and industry leaders, helping to guide investors, operators and regulators through this transient phase. Download your free copy now.
The Psychedelics as Medicine Report: Second Edition examines:
- Proprietary consumer insights on attitudes, uses and behaviours
- Deep dives into the most transformative compounds and companies
- Key regulations, transformative trends and commercial opportunities
HIGHLIGHTS
PSYCH: What are the next steps
for investors?
PSYCH: What Lies Ahead?
The Future of Therapy
PSYCH: Psychedelics for
Substance Use
PSYCH: Lessons Learned from 50 Years of Psychedelic Activism
NEWS AND INSIGHTS
The Horizons ETFs Makes Q1 Update
The main exchange for listing psychedelics companies, Horizons Psychedelic Stock Index ETF, has completed its first quarterly rebalance of its holdings. Horizons ETFs has over US$17.5 billion of assets under management and 88 ETFs listed on major Canadian stock exchanges. Four psychedelics industry businesses have been added to the index, which includes: Algernon Pharmaceuticals, BetterLifeContinue reading
Australia to Provide $15m to Support Research into Psychedelic Medicines
Last week, the Australian government announced it would provide $15m of funding to support research into psychedelic medicines and their impact on treating mental health conditions. The Mental Illness Grant Opportunity represents a new approach towards the likes of psilocybin, MDMA and Ketamine for Australia, where it is hoped that further legislative action and researchContinue reading
First ketamine-assisted psychotherapy clinic opens in the UK
Laurie Higbed, Ben Sessa and Steve O’Brien: Awakn Life Sciences | Photograph: Joel Redman/The Guardian Awakn Life Sciences has opened a clinic offering ketamine-assisted psychotherapy in the UK, becoming the first of its kind in the country. The clinic’s lead, Dr Ben Sessa, said he wants to harness the “unique mental state” he claims theContinue reading
THE PSYCHEDELICS NEWSLETTER
Expert analysis and intelligence, straight to your inbox. Join industry insiders and subscribe for exclusive news, data and insights from across the psychedelics industry.
